AstraZeneca (AZN) on Friday announced a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat ...

The latest announcement is out from AstraZeneca ( (AZN) ). On June 13, 2025, AstraZeneca announced a strategic research collaboration with CSPC Pharmaceuticals to advance AI-enabled drug discovery.

Editor Maria Ponnezhath Stock Markets Editor Maria Ponnezhath Published06/13/2025, 04:46 AM AstraZeneca partners with CSPC in deal worth up to $5.33 billion View all comments (0)0 AZN 1.29% ...

CSPC will conduct the research at its facilities in Shijiazhuang City using its AI-driven drug discovery platform. "This strategic research collaboration underscores our commitment to innovation to ...

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance ...

Friday’s agreement follows AstraZeneca’s announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with ...

AstraZeneca said it would have access to CSPC's pre-clinical candidate small molecule - YS2302018 - an oral Lp (a) disruptor, with the aim to develop it as a lipid-lowering therapy.

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

AstraZeneca has licensed a small-molecule lipoprotein disruptor from China’s CSPC Pharmaceutical Group for $100 million. The molecule is intended to prevent formation of lipoprotein(a), high ...

Under the terms of the agreement, CSPC will receive $110 million as an upfront payment. The deal also includes potential milestone payments of up to $5.22 billion. The partnership aims to strengthen ...